UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease
Condition: COVID-19 Infection Intervention: Drug: ursodeoxycholic acid Sponsor: Beijing Ditan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2023 Category: Research Source Type: clinical trials
The HAVEN study —hydroxychloroquine in ANCA vasculitis evaluation—a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan
DiscussionThis trial aims to explore Hydroxychloroquine as a treatment for patients with AAV. If effective, the need for immunosuppressive treatments such as prednisolone could be reduced. Hydroxychloroquine is safer, cheaper and has fewer adverse effects than conventional immunosuppressive treatments. This could improve patient outcomes while saving money for the NHS.Trial registrationISRCTN: ISRCTN79334891. Registered 07 June 2021.EudraCT: 2018-001268-40. Registered 13 September 2019.Clinicaltrials.gov: NCT04316494. Registered 20 March 2020. (Source: Trials)
Source: Trials - April 6, 2023 Category: Research Source Type: clinical trials
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
TARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
